Stock Scorecard
Stock Summary for Vaxcyte Inc (PCVX) - $53.00 as of 2/2/2026 8:52:39 AM EST
Total Score
8 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PCVX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PCVX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PCVX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PCVX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PCVX (37 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for PCVX
Financial Details for PCVX
Company Overview |
|
|---|---|
| Ticker | PCVX |
| Company Name | Vaxcyte Inc |
| Country | N/A |
| Description | Vaxcyte, Inc. (PCVX) is an innovative biotechnology company headquartered in Foster City, California, focused on the development of next-generation vaccines to combat global infectious diseases. Leveraging its proprietary technology platform, Vaxcyte is advancing a robust pipeline of vaccine candidates designed to elicit strong immune responses and address substantial unmet medical needs. With an unwavering commitment to research and development, the company is well-positioned to make significant contributions to public health and reshape the vaccine landscape, with a particular emphasis on improving patient outcomes and enhancing global health security. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/24/2026 |
Stock Price History |
|
| Last Day Price | 53.00 |
| Price 4 Years Ago | 47.95 |
| Last Day Price Updated | 2/2/2026 8:52:39 AM EST |
| Last Day Volume | 600,620 |
| Average Daily Volume | 1,267,026 |
| 52-Week High | 93.77 |
| 52-Week Low | 27.66 |
| Last Price to 52 Week Low | 91.61% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.68 |
| Sector PE | 188.49 |
| 5-Year Average PE | -15.03 |
| Free Cash Flow Ratio | 24.65 |
| Industry Free Cash Flow Ratio | 12.86 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 8.83 |
| Total Cash Per Share | 2.15 |
| Book Value Per Share Most Recent Quarter | 22.25 |
| Price to Book Ratio | 2.44 |
| Industry Price to Book Ratio | 64.54 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.05 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 130,906,000 |
| Market Capitalization | 6,938,018,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -15.33% |
| Reported EPS 12 Trailing Months | -4.85 |
| Reported EPS Past Year | -3.82 |
| Reported EPS Prior Year | -3.80 |
| Net Income Twelve Trailing Months | -657,201,000 |
| Net Income Past Year | -463,927,000 |
| Net Income Prior Year | -402,266,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 281,080,000 |
| Total Cash Past Year | 387,878,000 |
| Total Cash Prior Year | 397,451,000 |
| Net Cash Position Most Recent Quarter | 281,080,000 |
| Net Cash Position Past Year | 387,878,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 450,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 3,305,819,000 |
| Total Stockholder Equity Prior Year | 1,240,468,000 |
| Total Stockholder Equity Most Recent Quarter | 2,892,882,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -630,486,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -4.82 |
| Free Cash Flow Past Year | -475,054,000 |
| Free Cash Flow Prior Year | -364,667,000 |
Options |
|
| Put/Call Ratio | 1.45 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.82 |
| MACD Signal | 1.19 |
| 20-Day Bollinger Lower Band | 34.86 |
| 20-Day Bollinger Middle Band | 44.94 |
| 20-Day Bollinger Upper Band | 55.01 |
| Beta | 1.34 |
| RSI | 58.27 |
| 50-Day SMA | 42.56 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/31/2026 5:33:10 AM EST |